F-10POS: Oncolytics Biotech Deregisters Unsold Securities
Deregistration Statement
Oncolytics Biotech Inc. filed a post-effective amendment to deregister unsold portions of securities from multiple previous shelf registration statements.
Summary
- Oncolytics Biotech Inc. has filed Post-Effective Amendment No. 1 to several Form F-10 Registration Statements with the U.S. Securities and Exchange Commission (SEC).
- The purpose of these amendments is the deregistration of unsold portions of various securities, including units, common shares, subscription receipts, warrants, and debt securities, that were previously registered under ten different Form F-10 statements.
- These original registration statements were initially filed between February 2, 2007, and July 25, 2024.
- The company formally withdraws these registration statements, including all amendments and exhibits, specifically for the unsold securities.
- The deregistration is scheduled to become effective on April 7, 2026, at 10:00 p.m. Eastern time.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing with no direct positive or negative impact on the company's operational or financial performance. It is a procedural step to close out previous registration statements.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that the deregistration of unsold securities from previous shelf registration statements is a routine administrative action for publicly traded companies. It typically occurs when a company has completed its capital raising activities under a specific shelf registration or no longer requires the capacity to issue securities under those particular filings. This action does not inherently signal a change in the company's operational strategy or financial health but rather a formal closure of past offering capabilities.
Stakeholder Impact
- Shareholders: The deregistration formally closes the ability to issue additional securities under these specific, older shelf registration statements, which could be seen as a minor administrative update without direct impact on current share value or ownership dilution from these specific filings.
Next Steps
- The deregistration of securities will become effective on April 7, 2026, at 10:00 p.m. Eastern time.
Key Dates
| Date | Description |
|---|---|
| 2007-02-02 | Initial filing date of Registration Statement on Form F-10 (File No. 333-140460). |
| 2007-02-08 | Initial filing date of Registration Statement on Form F-10 (File No. 333-140529). |
| 2008-06-06 | Initial filing date of Registration Statement on Form F-10 (File No. 333-151513). |
| 2010-06-02 | Initial filing date of Registration Statement on Form F-10 (File No. 333-167250). |
| 2012-06-21 | Initial filing date of Registration Statement on Form F-10 (File No. 333-182260). |
| 2014-07-25 | Initial filing date of Registration Statement on Form F-10 (File No. 333-197633). |
| 2018-04-25 | Initial filing date of Registration Statement on Form F-10 (File No. 333-224432). |
| 2020-06-08 | Initial filing date of Registration Statement on Form F-10 (File No. 333-239025). |
| 2022-06-10 | Initial filing date of Registration Statement on Form F-10 (File No. 333-265510). |
| 2024-07-25 | Initial filing date of Registration Statement on Form F-10 (File No. 333-281009). |
| 2026-03-31 | Filing date of the Post-Effective Amendment No. 1 to Form F-10. |
| 2026-04-07 | Proposed effective date of the deregistration at 10:00 p.m. Eastern time. |
Keywords
Oncolytics Biotech, SEC filing, F-10POS, Deregistration, Securities Act of 1933, Shelf Registration, Unsold Securities, Common Shares, Units, Warrants, Debt Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.